ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients

Sponsor
National Taiwan University Hospital
Study ID
NCT07322627
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Study Details

Alcohol consumption, smoking, and betel nut chewing have been proven to be closely associated with the risk of esophageal cancer (EC). Recent studies have shown that alcohol-related detoxification genes in the ALDH family influence individual susceptibility to esophageal cancer. Aldehyde dehydrogenase 2 (ALDH2) is one of the most important enzymes in the ALDH family, involved in the metabolism of alcohol, acetaldehyde, and environmental aldehydes in the human body. We hypothesize that functional variations in ALDH2 may have a significant impact on the survival of esophageal cancer patients. This study aims to investigate the correlation between ALDH2 gene polymorphism and the survival of esophageal cancer patients.

Key Dates

First listed
Jan 7, 2026
Start date
Dec 8, 2025
Status verified
Dec 2025
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
700 participants (estimated)

Primary Outcome Measure

death [ Time Frame: from the date of first diagnosis or undergoing esophagectomy to the end of 2024 ]

Central Contacts

Find similar trials

Nationwide
Esophageal cancer trialsOncology trialsGI oncology trials

Related Studies